Moderna's mFlusiva was approved Aug. 5, 2026, as the first mRNA flu vaccine in the U.S., authorized for adults 50 and older (full approval 50–64; accelerated approval 65+ pending further study). In trials of over 40,000 participants, it cut laboratory-confirmed influenza cases by about 27% versus a standard vaccine and generated robust immune responses. Short-term side effects — injection-site pain, fatigue, headache, fever and muscle aches — were more common than with some existing shots, but no major safety issues were identified. Experts still recommend combining vaccination with handwashing, distancing from sick people, and staying home when ill to reduce spread.
First mRNA Flu Vaccine Approved for Older Adults — Vaccination Plus Simple Habits Still Matter
Photo by Getty Images
On Aug. 5, 2026, the U.S. Food and Drug Administration granted approval to mFlusiva, Moderna's mRNA influenza vaccine — the first mRNA-based flu shot authorized in the United States. The vaccine is authorized for adults aged 50 and older, with full approval for those 50–64 and accelerated approval for people 65 and older pending a follow-up study to confirm benefits in the oldest cohort.
Trial Results and Effectiveness
Moderna evaluated mFlusiva in a clinical trial involving more than 40,000 adults age 50 and up. According to trial data reported by The Associated Press and FDA documents, recipients of mFlusiva had about 27% fewer laboratory-confirmed influenza cases compared with people who received a standard seasonal flu vaccine. The vaccine is formulated to protect against the A and B influenza strains included in that season's vaccine composition.
Comparison With High-Dose Vaccines and Safety
Moderna also compared the mRNA shot with a high-dose influenza vaccine commonly given to older adults. The mRNA formulation produced a strong immune response, a key factor supporting its accelerated approval for people 65 and older. Investigators reported no major safety concerns; however, short-term side effects — including pain at the injection site, fatigue, headache, fever and muscle aches — occurred somewhat more often with mFlusiva than with some existing flu vaccines.
How mRNA Vaccines Work and Why It Matters
Unlike many traditional flu vaccines made using eggs or cell cultures, an mRNA vaccine delivers genetic instructions that prompt cells to produce a harmless viral protein. That protein trains the immune system to recognize and fight the influenza virus. Because the mRNA platform is easier to update than older methods, it could speed formulation changes when circulating flu strains drift.
Regulatory Notes and Availability
The FDA's decision follows earlier back-and-forth between Moderna and regulators over trial comparators; the agency initially declined to review Moderna's application but later accepted it. Limited supplies of mFlusiva could arrive at select U.S. retailers for the fall 2026 flu season, with broader availability dependent on manufacturing and distribution plans.
Practical Prevention Tips
Health officials emphasize that vaccination is one important layer of protection, but everyday habits also reduce flu spread. A systematic review published in Influenza and Other Respiratory Viruses found that hand-hygiene programs and similar measures can lower transmission of influenza and other respiratory infections, though effectiveness varies by setting and adherence.
Practical advice: Wash your hands regularly, avoid touching your eyes, nose and mouth, keep distance from people who are sick, stay home if you develop symptoms, and cover coughs and sneezes to limit onward transmission.
In short: mFlusiva represents a promising advance in flu prevention for older adults, but combining vaccination with simple hygiene and social measures provides the strongest protection during flu season.
Help us improve.
